Skip to main content
NCBI home page
The Ulster Medical Journal logoLink to The Ulster Medical Journal
. 1991 Oct;60(2):229–234.

Rapidly progressive obstructive jaundice due to Congo red negative amyloidosis.

B M McClements 1, J H Shanks 1, C M Hill 1, C H Cameron 1, M E Callender 1
PMCID: PMC2448642  PMID: 1785159

Full text

PDF
229

Images in this article

230Fig 1
on p.230
231Fig 2
on p.231
232Fig 3
on p.232

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradstock K., Clancy R., Uther J., Basten A., Richards J. The successful treatment of primary amyloidosis with intermittent chemotherapy. Aust N Z J Med. 1978 Apr;8(2):176–179. doi: 10.1111/j.1445-5994.1978.tb04507.x. [DOI] [PubMed] [Google Scholar]
  2. Calomeni J. A., Smith J. R. Obstructive jaundice from hepatic amyloidosis in a patient with multiple myeloma. Am J Hematol. 1985 Jul;19(3):277–279. doi: 10.1002/ajh.2830190309. [DOI] [PubMed] [Google Scholar]
  3. Fred H. L., Robie P. Dizzy medical writing: Part II. South Med J. 1984 Jun;77(6):755–756. doi: 10.1097/00007611-198406000-00022. [DOI] [PubMed] [Google Scholar]
  4. Gertz M. A., Kyle R. A. Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med. 1988 Jul;85(1):73–80. doi: 10.1016/0002-9343(88)90505-0. [DOI] [PubMed] [Google Scholar]
  5. Gertz M. A., Kyle R. A. Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature. Mayo Clin Proc. 1986 Mar;61(3):218–223. doi: 10.1016/s0025-6196(12)61853-9. [DOI] [PubMed] [Google Scholar]
  6. Horne M. K., 3rd Letter: Improvement in amyloidosis. Ann Intern Med. 1975 Aug;83(2):281–282. doi: 10.7326/0003-4819-83-2-281. [DOI] [PubMed] [Google Scholar]
  7. Konikoff F., Mor C., Stern S., Shaklai M., Halevy J., Theodor E. Cholestasis and liver failure with lambda-AL amyloidosis. Gut. 1987 Jul;28(7):903–906. doi: 10.1136/gut.28.7.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kyle R. A., Greipp P. R. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983 Oct;58(10):665–683. [PubMed] [Google Scholar]
  9. Levy M., Polliack A., Lender M., Eliakim M. The liver in amyloidosis. Digestion. 1974;10(1):40–51. doi: 10.1159/000197521. [DOI] [PubMed] [Google Scholar]
  10. Melato M., Manconi R., Magris D., Morassi P., Benussi D. G., Tiribelli C. Different morphologic aspects and clinical features in massive hepatic amyloidosis. Digestion. 1984;29(3):138–145. doi: 10.1159/000199023. [DOI] [PubMed] [Google Scholar]
  11. Rubinow A., Koff R. S., Cohen A. S. Severe intrahepatic cholestasis in primary amyloidosis: a report of four cases and a review of the literature. Am J Med. 1978 Jun;64(6):937–946. doi: 10.1016/0002-9343(78)90447-3. [DOI] [PubMed] [Google Scholar]
  12. Scheinberg M. A., Pernambuco J. C., Benson M. D. DMSO and colchicine therapy in amyloid disease. Ann Rheum Dis. 1984 Jun;43(3):421–423. doi: 10.1136/ard.43.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Skander M. P., Harry D. S., Lee F. I. Severe intrahepatic cholestasis and rapidly progressive renal failure in a patient with immunocyte-related amyloidosis. J Clin Gastroenterol. 1987 Apr;9(2):219–222. doi: 10.1097/00004836-198704000-00023. [DOI] [PubMed] [Google Scholar]

Articles from The Ulster Medical Journal are provided here courtesy of Ulster Medical Society

RESOURCES